Showing results (91-100 of 102) with videos related to
Sort By:
Pageof 11
Liver International : Official Journal of the International Association for the Study of the Liver|July 15, 2023
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world dataMargherita Rimini, Lorenzo Fornaro, Sara Lonardi, et al.Targeted Oncology|May 1, 2024
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter StudyMargherita Rimini, Gianluca Masi, Sara Lonardi, et al.ESMO Open|August 30, 2017
Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trialE Martinelli, C Cardone, T Troiani, et al.European Journal of Cancer (Oxford, England : 1990)|July 13, 2024
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide populationMargherita Rimini, Lorenzo Fornaro, Mario Domenico Rizzato, et al.The Oncologist|October 19, 2024
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide populationFederica Lo Prinzi, Francesca Salani, Margherita Rimini, et al.Oncology|August 15, 2025
Impact of antibiotic therapy in patients with cholangiocarcinoma treated with chemoimmunotherapyFrancesco Vitiello, Caterina Vivaldi, Mario Domenico Rizzato, et al.Targeted Oncology|February 27, 2026
Prognostic Impact of Metastatic Sites in Patients with Biliary Tract Cancer Treated with Cisplatin, Gemcitabine, and DurvalumabSilvia Camera, Lorenzo Fornaro, Margherita Rimini, et al.International Journal of Cancer|May 19, 2025
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real-world results from a multicenter and multinational studyMargherita Rimini, Lorenzo Fornaro, Federica Lo Prinzi, et al.Journal of the National Cancer Institute|July 3, 2025
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine and durvalumab: a large real-life worldwide populationMargherita Rimini, Lorenzo Fornaro, Federica Lo Prinzi, et al.International Journal of Cancer|July 11, 2025
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real-life worldwide populationFederica Lo Prinzi, Francesca Salani, Silvia Camera, et al.Pageof 11